Due to the special nature of medicines, returns and exchanges are not supported.
Final delivery from the nearest overseas warehous NEW

Ripertamab Injection

This product is suitable for newly diagnosed adult patients with CD20-positive diffuse large B-cell non-Hodgkin’s lymphoma (DLBCL) with an international prognostic index (IPI) of 0 to 2 points. It should be treated in combination with standard CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisone).
Repatuzumab is a human-mouse chimeric monoclonal antibody that can specifically bind to the transmembrane antigen CD20. The CD20 antigen is located on the surface of pre-B and mature B lymphocytes. After binding to the CD20 antigen on B cells, this product initiates an immune response to mediate B cell lysis. The mechanisms of B cell lysis may include: complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC).

Share: